Sign in
Taking peopleNo phase

ECG Findings in Methamphetamine Use

Key facts

Who runs it
Elazığ Mental Health and Diseases Hospital
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
240 people, planned
Started
7 Apr 2025
Expected to end
22 Dec 2026
Type of study
Observational, 3 groups
Record updated
10 September 2026

Who can take part

Age
18 years to 65 years
Sex
Men only
Healthy volunteers
Can take part
Show the full registry criteria (3)Hide the full registry criteria

Other criteria

  • For Methamphetamine Use Disorder (MUD) Group:; *Inclusion Criteria:; Diagnosis of MUD according to DSM-5-TR; Medication-free for at least one month prior to admission; Age ≥ 18 years and <65 years; Provided informed consent; For Methamphetamine Use Disorder (MUD) Group:; *Exclusion Criteria:; Hypertension; Diabetes mellitus; Chronic kidney disease; Rheumatoid arthritis; Systemic lupus erythematosus; Cardiac illness; Severe neurological disorders; Immunological or systemic illness; Primary psychiatric disorders other than MUD; Alcohol use disorder
  • For Methamphetamine-Induced Psychotic Disorder (MP) Group:; *Inclusion Criteria:; Diagnosis of MP according to DSM-5-TR; Medication-free for at least one month prior to admission; Age ≥ 18 years and <65 years; Provided informed consent; For Methamphetamine-Induced Psychotic Disorder (MP) Group:; *Exclusion Criteria:; Hypertension; Diabetes mellitus; Chronic kidney disease; Rheumatoid arthritis; Systemic lupus erythematosus; Cardiac illness; Severe neurological disorders; Immunological or systemic illness; Primary psychiatric disorders other than MP; Alcohol use disorder
  • For Healthy Control Group:; *Inclusion Criteria:; No psychiatric diagnosis; No systemic or immunological illness; Medication-free for at least one month; Age ≥ 18 years and <65 years; Provided informed consent; For Healthy Control Group:; *Exclusion Criteria:; Hypertension; Diabetes mellitus; Chronic kidney disease; Rheumatoid arthritis; Systemic lupus erythematosus; Cardiac illness; Severe neurological disorders; Immunological or systemic illness; Primary psychiatric disorders other than schizophrenia; Alcohol/drug/substance use

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Methamphetamine use disorder or methamphetamine induced psychosis

This trial is currently available in Türkiye.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective cohort study aims to examine and compare electrocardiogram (ECG) parameters in subjects diagnosed with Methamphetamine Use Disorder (MUD) and Methamphetamine-Induced Psychotic Disorder (MP) during inpatient psychiatric treatment. ECG findings at hospital admission and during remission prior to discharge will be evaluated and compared between groups. The study also aims to determine whether methamphetamine-induced psychosis is associated with greater ECG abnormalities and increased cardiac risk compared to methamphetamine use without psychosis.

The 3 groups in the trial

  • Methamphetamine Use Disorder (MUD)

    Adult participants (18-65 years) diagnosed with Methamphetamine Use Disorder according to DSM-5-TR criteria. No intervention was/will be assigned by the study protocol. Participants were/will be evaluated at baseline and after 6 weeks of routine clinical treatment. Electrocardiogram (ECG) and complete blood count were/will be obtained from participants at baseline and after six weeks of follow-up. No psychometric scales were/will be administered to this group. Sociodemographic and clinical data were/will be recorded for all participants.

  • Methamphetamine-Induced Psychotic Disorder (MP)

    Adult participants (18-65 years) diagnosed with Methamphetamine-Induced Psychotic Disorder according to DSM-5-TR criteria. No intervention was/will be assigned by the study protocol. Participants were/will be evaluated at baseline and after 6 weeks of routine clinical treatment. Electrocardiogram (ECG) and complete blood count were/will be obtained from participants at baseline and after six weeks of follow-up. Psychotic symptom severity was/will be assessed using the Positive and Negative Syndrome Scale (PANSS). Insight Assessment Scale (IAS) was/will be used to measure the insight level. Sociodemographic and clinical data were/will be recorded for all participants.

  • Healthy Control (HC)

    Healthy control (HC) adult participants (18-65 years) without any current or past psychiatric disorder. No intervention was administered as part of the research protocol. Participants underwent a baseline clinical evaluation and provided a single blood sample for measurement of complete blood count. Sociodemographic and clinical data were recorded for all participants. As of December 15, 2025, the recruitment of HC participants has been completed.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Electrocardiogram Findings in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Prospective Observational Cohort Study
Criteria questions
Built from NCT07459244, who can take part
Record updated
10 September 2026